ABSTRACT
Background:
Resistance of malaria vectors to different classes of insecticides has been reported in malaria-endemic areas. Identifying new indoor residual spray (IRS) compounds that are effective against resistant vector populations is a high priority in managing insecticide resistance.
Method:
A biological efficacy trial was conducted in the field from August 2016 to February 2017 to determine the efficacy of SumiShield 50WG, a new insecticide class, against wild Anopheles arabiensis. Indoor surfaces of 20 houses in Mabogini ward in the rural district of Moshi in northern Tanzania were sprayed with SumiShield 50WG. Bio-efficacy monitoring was conducted monthly for 6 months after the spray application. In addition, susceptibility tests were conducted by exposing mosquitoes to papers treated with permethrin 0.75%, pirimiphos-methyl 0.25%, and clothianidin 2% (SumiShield 50WG). Representatives from each household included in the study were surveyed about possible side effects or problems faced since the spray. Regression probit analysis was used to calculate knock-down times while the chi-square test was used to compare the mortality effect for mosquitoes.
Results:
The SumiShield 50WG insecticide maintained optimal efficacy in the field setting for the duration of the 6-month study period, with 100% mortality of mosquitoes by 144 to 168 hours post-exposure to treated surfaces. Susceptibility tests showed some variation in tolerance to the tested insecticide-treated papers, particularly between SumiShield 50WG and pirimiphos-methyl. The knock-down times for 50% and 95% of the mosquitoes when exposed to SumiShield 50WG-treated test paper were 45.81 minutes and 83.85 minutes, respectively, and 67.77 minutes and 105.81 minutes, respectively, for the pirimiphos-methyl-treated papers. There were no short-term adverse side effects reported by households sprayed with SumiShield 50WG.
Conclusion:
The findings of this study suggest that SumiShield 50WG is a viable IRS insecticide for malaria vector control in Tanzania, especially in areas where pyrethroid resistance is a concern.
- Received: June 7, 2018.
- Accepted: November 13, 2018.
- Published: December 27, 2018.
- © Kweka et al.
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly cited. To view a copy of the license, visit http://creativecommons.org/licenses/by/4.0/. When linking to this article, please use the following permanent link: https://doi.org/10.9745/GHSP-D-18-00213